Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

1.

In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions.

Mbunwe E, Van der Auwera BJ, Weets I, Van Crombrugge P, Crenier L, Coeckelberghs M, Seret N, Decochez K, Vandemeulebroucke E, Gillard P, Keymeulen B, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers DG, Gorus FK; Belgian Diabetes Registry.

Diabetologia. 2013 Sep;56(9):1964-70. doi: 10.1007/s00125-013-2951-8. Epub 2013 May 28.

2.

HLA-A*24 is an independent predictor of 5-year progression to diabetes in autoantibody-positive first-degree relatives of type 1 diabetic patients.

Mbunwe E, Van der Auwera BJ, Vermeulen I, Demeester S, Van Dalem A, Balti EV, Van Aken S, Derdelinckx L, Dorchy H, De Schepper J, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers D, Weets I, Gorus FK; Belgian Diabetes Registry.

Diabetes. 2013 Apr;62(4):1345-50. doi: 10.2337/db12-0747. Epub 2012 Nov 16.

3.

Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing's syndrome.

Preumont V, Mermejo LM, Damoiseaux P, Lacroix A, Maiter D.

Horm Metab Res. 2011 Apr;43(4):287-91. doi: 10.1055/s-0030-1270523. Epub 2011 Jan 24.

PMID:
21264796
4.

One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice.

Buysschaert M, Preumont V, Oriot PR, Paris I, Ponchon M, Scarnière D, Selvais P; UCL Study Group for Exenatide.

Diabetes Metab. 2010 Nov;36(5):381-8. doi: 10.1016/j.diabet.2010.03.009. Epub 2010 Jul 2.

5.

Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients.

Vandemeulebroucke E, Keymeulen B, Decochez K, Weets I, De Block C, Féry F, Van de Velde U, Vermeulen I, De Pauw P, Mathieu C, Pipeleers DG, Gorus FK; Belgian Diabetes Registry.

Diabetologia. 2010 Jan;53(1):36-44. doi: 10.1007/s00125-009-1569-3. Epub 2009 Nov 7.

PMID:
19898832
6.
7.

[Epidemic of hantavirus disease in Entre-Sambre-et-Meuse: year 1992-1993. Clinical and biological aspects].

Colson P, Damoiseaux P, Brisbois J, Duvivier E, Levecque P, Roger JM, Bouilliez DJ, McKenna P, Clement J.

Acta Clin Belg. 1995;50(4):197-206. French.

PMID:
7483970
8.

Hantavirus epidemic in Europe, 1993.

Clement J, McKenna P, Colson P, Damoiseaux P, Penalba C, Halin P, Lombart D.

Lancet. 1994 Jan 8;343(8889):114. No abstract available.

PMID:
7903742
9.

[Sarcoidosis and hyperthyroidism].

Damoiseaux P, Gianasso P.

Acta Clin Belg. 1988;43(5):344-8. French. No abstract available.

PMID:
3206974
10.

[Icterohemorrhagic leptospirosis: apropos of 5 case reports].

Bigaignon G, Colin JF, Mulumba M, Damoiseaux P, Gohy P, Lens E, Passelecq E, Rosoux A, Reynaert M, Piot P.

Acta Clin Belg. 1988;43(4):273-81. French. No abstract available.

PMID:
3188801
11.
12.

[Unique episode of acute pancreatitis manifesting familial hypocalciuric hypercalcemia].

Damoiseaux P, Tafforeau M, Henkinbrant A.

Acta Clin Belg. 1985;40(4):247-50. French. No abstract available.

PMID:
4082863
13.

Insulin resistance in Type 1 (insulin-dependent) diabetes: dependence on plasma insulin concentration.

Pernet A, Trimble ER, Kuntschen F, Damoiseaux P, Assal JP, Hahn C, Renold AE.

Diabetologia. 1984 Apr;26(4):255-60.

PMID:
6376232
14.

[Pulmonary embolism and cardiac pacemakers].

Damoiseaux P, Schoevaerdts JC, de Fays F, Weynants P, Marchandise B, Buysschaert M.

Acta Clin Belg. 1983;38(2):134-5. French. No abstract available.

PMID:
6868937
15.

Effect of Acarbose on blood glucose profile of totally insulin-dependent diabetic patients.

Damoiseaux P, Buysschaert M, Ketelslegers JM, Hillebrand IS, Lambert AE.

Acta Clin Belg. 1983;38(1):5-11. No abstract available.

PMID:
6342321
16.

[Membrane proteins. I. Chemical modification of tyrosyl residues].

Damoiseaux P, Vincentelli JB, Léonis J.

Arch Int Physiol Biochim. 1974 Feb;82(1):175. French. No abstract available.

PMID:
4136402
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk